You just read:

European Hematology Association: Clinical and Biologic Covariates of Outcomes in ZUMA-1: A Pivotal Trial of Axicabtagene Ciloleucel (axi-cel; KTE-C19) in Patients with Refractory Aggressive non-Hodgkin Lymphoma (NHL)

News provided by

European Hematology Association

24 Jun, 2017, 07:30 BST